Bilal Piperdi

Merck & Co., Inc., Rahway, NJ, USA (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer”.

First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer

Lung Cancer(2021)10.1016/j.lungcan.2021.02.015

N/A

0.792DataRank · unranked

18 citations

Yiyu Zou, Chirag Shah, Ni Fan, Tushar D. Bhagat, Rasim Gucalp +7 more

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer(2020)10.1002/cncr.33142

N/A

0DataRank · unranked

111 citations

Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino +8 more

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100205

N/A

0DataRank · unranked

84 citations

Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong‐Wan Kim +12 more